[
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?",
    "summary": "We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors favor blue chip stocks due to their […]",
    "url": "https://finnhub.io/api/news?id=135d0646fdf6e244865001c12830d80ddf01fc1a8fd664e2b98fab6b80f4a5f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736456577,
      "headline": "Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?",
      "id": 132357053,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors favor blue chip stocks due to their […]",
      "url": "https://finnhub.io/api/news?id=135d0646fdf6e244865001c12830d80ddf01fc1a8fd664e2b98fab6b80f4a5f8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea",
    "summary": "Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.",
    "url": "https://finnhub.io/api/news?id=e0540c28935ef448fe82ed6d8013a335a50bf55ecae41b1c54efb34a15aacb00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736455008,
      "headline": "Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea",
      "id": 132354300,
      "image": "https://www.investopedia.com/thmb/1Al6yUm6eeULcNDtRYzddJjl5cg=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2126120481-f80ae43f31204df79378fee13e344f48.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.",
      "url": "https://finnhub.io/api/news?id=e0540c28935ef448fe82ed6d8013a335a50bf55ecae41b1c54efb34a15aacb00"
    }
  },
  {
    "ts": null,
    "headline": "Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge.",
    "summary": "The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that afflicts many severely obese people.",
    "url": "https://finnhub.io/api/news?id=8556098423a95c5c068c6071fa91d81edd76c899e34117fb31277b8b8448e019",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736441580,
      "headline": "Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge.",
      "id": 132357056,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that afflicts many severely obese people.",
      "url": "https://finnhub.io/api/news?id=8556098423a95c5c068c6071fa91d81edd76c899e34117fb31277b8b8448e019"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy",
    "summary": "Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.",
    "url": "https://finnhub.io/api/news?id=efb24f52bedda28142dcff3dd813536d138d2cfe0188ffd495a0a0c8a290a62e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736435100,
      "headline": "NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy",
      "id": 132354301,
      "image": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.",
      "url": "https://finnhub.io/api/news?id=efb24f52bedda28142dcff3dd813536d138d2cfe0188ffd495a0a0c8a290a62e"
    }
  },
  {
    "ts": null,
    "headline": "LLY Falls Around 14% in 3 Months: How to Play the Stock",
    "summary": "Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.",
    "url": "https://finnhub.io/api/news?id=cf082d330fa178aa5e296a5b10f7f05eae09f0c58b3df83a2d5049aa39278a23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736428680,
      "headline": "LLY Falls Around 14% in 3 Months: How to Play the Stock",
      "id": 132354302,
      "image": "https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.",
      "url": "https://finnhub.io/api/news?id=cf082d330fa178aa5e296a5b10f7f05eae09f0c58b3df83a2d5049aa39278a23"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
    "summary": "Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.",
    "url": "https://finnhub.io/api/news?id=0622b5dd71ba4d46b5d12049e3d283a02a5e7da194b12486ae101a4795827d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736427603,
      "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
      "id": 132349387,
      "image": "https://media.zenfs.com/en/ibd.com/e1eeaef96933bc3e739bae513ec3f5e4",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.",
      "url": "https://finnhub.io/api/news?id=0622b5dd71ba4d46b5d12049e3d283a02a5e7da194b12486ae101a4795827d78"
    }
  },
  {
    "ts": null,
    "headline": "5 questions facing pharma in 2025",
    "summary": "Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.",
    "url": "https://finnhub.io/api/news?id=2918e31f356865b1e723a958cbee8482685044028585db5742ff1caf2c84812c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736424780,
      "headline": "5 questions facing pharma in 2025",
      "id": 132354303,
      "image": "https://imgproxy.divecdn.com/SupXMWEe4BV9YE-Vn-XKUgXhXiXVh1DWmO81tffZGDw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTkyODQ2NTA4MS5qcGc=.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.",
      "url": "https://finnhub.io/api/news?id=2918e31f356865b1e723a958cbee8482685044028585db5742ff1caf2c84812c"
    }
  },
  {
    "ts": null,
    "headline": "Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly",
    "summary": "Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly",
    "url": "https://finnhub.io/api/news?id=f9da5f52f62d29a418a97a5e379e4147d91e1a109e6d5cb9828074100f4b5c40",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736420460,
      "headline": "Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly",
      "id": 132407713,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly",
      "url": "https://finnhub.io/api/news?id=f9da5f52f62d29a418a97a5e379e4147d91e1a109e6d5cb9828074100f4b5c40"
    }
  },
  {
    "ts": null,
    "headline": "The most and least expensive weight loss drugs, ranked",
    "summary": "Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The medications, which belong to the class of drugs called GLP-1s and were popularized by the diabetes treatment Ozempic, help regulate blood sugar levels and suppress appetite.",
    "url": "https://finnhub.io/api/news?id=d3f66dc827c8f66602eb58323e39eccb6ca436e41dd26b45a60237c51b35cc26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736416800,
      "headline": "The most and least expensive weight loss drugs, ranked",
      "id": 132357062,
      "image": "https://media.zenfs.com/en/quartz.com/af68c06c226087b78e74a5dba253de21",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The medications, which belong to the class of drugs called GLP-1s and were popularized by the diabetes treatment Ozempic, help regulate blood sugar levels and suppress appetite.",
      "url": "https://finnhub.io/api/news?id=d3f66dc827c8f66602eb58323e39eccb6ca436e41dd26b45a60237c51b35cc26"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks to Buy for 2025 That Are Practically Money Machines",
    "summary": "You won't find many companies that rake in greater sales than Amazon (NASDAQ: AMZN).  The e-commerce and cloud services giant generated revenue of roughly $620 billion over the last 12 months.  The consensus revenue estimate for Amazon in 2025 among analysts surveyed by LSEG is around $707 billion.",
    "url": "https://finnhub.io/api/news?id=d3735be96d3b7512b5231d6bb06829afa21f3e82997a3e29ec88a8d420a22410",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736415240,
      "headline": "3 Stocks to Buy for 2025 That Are Practically Money Machines",
      "id": 132346153,
      "image": "https://g.foolcdn.com/editorial/images/803172/cash-100-bills.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "You won't find many companies that rake in greater sales than Amazon (NASDAQ: AMZN).  The e-commerce and cloud services giant generated revenue of roughly $620 billion over the last 12 months.  The consensus revenue estimate for Amazon in 2025 among analysts surveyed by LSEG is around $707 billion.",
      "url": "https://finnhub.io/api/news?id=d3735be96d3b7512b5231d6bb06829afa21f3e82997a3e29ec88a8d420a22410"
    }
  },
  {
    "ts": null,
    "headline": "LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy",
    "summary": "LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a buy.",
    "url": "https://finnhub.io/api/news?id=05d3d0c6eb00aab592c4bb564ef8328dc98e73184ddcafb701ef8fc5b95612bb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736411778,
      "headline": "LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy",
      "id": 132347253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178382825/image_2178382825.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a buy.",
      "url": "https://finnhub.io/api/news?id=05d3d0c6eb00aab592c4bb564ef8328dc98e73184ddcafb701ef8fc5b95612bb"
    }
  }
]